Clinical Trials in Breast Cancer
Research in a Nutshell
Prof. Cameron’s first degree was in mathematics from the University of Cambridge, and he received his medical degree in 1986 from St. George’s Hospital Medical School, London. After completing a fellowship and MSc in Clinical Oncology at the University of Edinburgh, he received a M.D. with distinction in 1997 and completed his training as a medical oncologist that same year. Prof. Cameron is a member of several professional societies including the American Society of Clinical Oncology, the European Society for Medical Oncology and is Chairperson of the European Organisation for Research and Treatment of Cancer (EORTC) Breast Cancer Group. He has also been a member of the EORTC task force on the use of growth factors in chemotherapy for solid tumours and lymphoma and a part chairman of the EORTC New Agent Committee. He has also recently chaired the cancer sub-group of the advisory group on the English NHS 100 000 genome project, the Scottish short-life working group on the use of unlicensed cancer medicines, and was a member of the Scottish Medicines Consortium (similar to NICE).
He will step down as the clinical director of the Edinburgh University Cancer Centre and CRUK Cancer Centre in order to take on the role of chair of the Breast International Group, a Brussels-based umbrella group of over 60 worldiwde academic/no-for-profit breast cancer trials’ groups, and to be vice chair of the steering group of the Oxford-based Early Breast Cancer Clinical Trialists’ Group. He will remain as the lead for the Edinburgh Experimental Cancer medicine centre
He is active in a number of current and past clinical trials in breast cancer. He is a member of the executive committee of the HERA adjuvant herceptin trial, and a member of the steering group for several UK adjuvant breast cancer trials (AZURE, OPTION, TACT, TANGO, MAMMO50, ARTEMIS, PERSEPHONE, ROSCO and TEAM) as well as the BIG APHINITY, ALTTO/NEO_ALTTO, BRAVO and AURORA studies. He is chief investigator on the UK trial adjuvant breast cancer trial, TACT2, and of BEATRICE, a global trial that tested the possible benefit of adjuvant bevacizumab in triple negative breast cancer. He jointly chaired the ENCHANT phase II study of an HSP90i in breast cancer.
Between November 2006 & June 2010 he was Director of the NIHR-funded National Cancer Research Networks, and at the end of 2009 took up a new post as Professor of Oncology at Edinburgh University and Director of Cancer Services in NHS Lothian.
He is a present and past member of several cancer research funding committees including INCA PHRC, PEAR, Cancer Research UK Science committee, Cancer Research UK Clinical Research Committee, and from time to time various NIHR funding bodies including EME, clinical trials fellows committee. He is on the advisory board of the ICR and Glasgow Clinical Trials Units, and the Bordeaux Institute Bergonie and Cardiff Cancer Clinical and Translational Research programmes.
Principal Investigator, Professor of Medical Oncology